Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cidara Therapeutics (CDTX) Income towards Parent Company: 2016-2024

Historic Income towards Parent Company for Cidara Therapeutics (CDTX) over the last 9 years, with Dec 2024 value amounting to $464,000.

  • Cidara Therapeutics' Income towards Parent Company fell 18396.22% to -$83.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$132.4 million, marking a year-over-year decrease of 2564.97%. This contributed to the annual value of $464,000 for FY2024, which is 78.41% down from last year.
  • Latest data reveals that Cidara Therapeutics reported Income towards Parent Company of $464,000 as of FY2024, which was down 78.41% from $2.1 million recorded in FY2023.
  • Over the past 5 years, Cidara Therapeutics' Income towards Parent Company peaked at $2.1 million during FY2023, and registered a low of -$72.1 million during FY2020.
  • For the 3-year period, Cidara Therapeutics' Income towards Parent Company averaged around -$10.3 million, with its median value being $464,000 (2024).
  • As far as peak fluctuations go, Cidara Therapeutics' Income towards Parent Company spiked by 106.40% in 2023, and later crashed by 78.41% in 2024.
  • Over the past 5 years, Cidara Therapeutics' Income towards Parent Company (Yearly) stood at -$72.1 million in 2020, then skyrocketed by 41.11% to -$42.5 million in 2021, then grew by 20.92% to -$33.6 million in 2022, then surged by 106.40% to $2.1 million in 2023, then plummeted by 78.41% to $464,000 in 2024.